Cas9 Stable Cell Line - HMC3

The HMC3-Cas9 stable cell line is the preferred experimental model for human microglia research. It is established by integrating the Cas9 nuclease into the genome of human microglia clone 3 (HMC3). HMC3 cells were originally obtained from primary microglia derived from SV40-dependent immortalized human fetal brain, providing a homogeneous cell population that retains key phenotypic markers of native microglia, such as IBA1 and CD14. By constitutively expressing the Cas9 enzyme, this cell line eliminates the variability and cytotoxicity associated with repeated transient transfections, ensuring high efficiency for both single-gene and multi-gene editing. The Cas9 nuclease in this cell line is typically driven by a strong promoter to maintain optimal expression levels, making it a reliable platform for functional genomics and high-throughput CRISPR screening aimed at elucidating molecular pathways in the human central nervous system.

The primary applications of the HMC3-Cas9 stable cell line are in the study of neuroinflammation and the development of therapeutic strategies for neurodegenerative diseases such as Alzheimer''s and Parkinson''s diseases. Researchers used this system for precise gene knockout and knock-in to study the roles of specific genes in microglia activation, cytokine secretion, and phagocytosis of β-amyloid (Aβ) aggregates. Furthermore, this cell line can serve as a convenient model for exploring the interactions between microglia and other components of the central nervous system, including neurons and astrocytes, during disease progression. The ability to rapidly screen guide RNA (sgRNA) libraries in the HMC3-Cas9 context enables researchers to identify novel regulators of the brain''s innate immune response, providing a powerful tool for drug discovery and validating therapeutic targets in a human-relevant cellular environment.